Longitudinal amyloid imaging in mouse brain with 11C-PIB: Comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1434-1441

  Snellman, Anniina ^a   López Picón, Francisco R ^a   Rokka, Johanna ^a   Salmona, Mario ^b   Forloni, Gianluigi ^b   Scheinin, Mika ^c   Solin, Olof ^a,d   Rinne, Juha O ^c   Haaparanta Solin, Merja ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

11C PIB; Alzheimer disease; Amyloid imaging; Pittsburgh compound B; Positron emission tomography

Indexed keywords

AMYLOID BETA N3 PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-16]; AMYLOID BETA PROTEIN[1-40]; PITTSBURGH COMPOUND B; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CEREBELLUM; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DISTRIBUTION VOLUME; DRUG PROTEIN BINDING; EX VIVO STUDY; FEMALE; FRONTAL CORTEX; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LONGITUDINAL STUDY; MALE; MOLECULAR IMAGING; MOUSE; NEOCORTEX; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

11C-PIB, PITTSBURGH COMPOUND B; ALZHEIMER DISEASE; AMYLOID IMAGING; POSITRON EMISSION TOMOGRAPHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTORADIOGRAPHY; BENZOTHIAZOLES; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; LONGITUDINAL STUDIES; MALE; MICE; MICE, TRANSGENIC; POSITRON-EMISSION TOMOGRAPHY;

EID: 84881392145     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.110163     Document Type: Article

References (24)

1. Nordberg A, Rinne JO, Kadir A, Långström B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6:78-87.
2. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
3. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
4. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(49- methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23:2086-2092.
5. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740-2754.
6. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008;115:5-38.
7. Dodart JC, Mathis C, Bales KR, Paul SM. Does my mouse have Alzheimer's disease? Genes Brain Behav. 2002;1:142-155.
8. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron. 2010;66:631-645.
9. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2005;32:593-600.
10. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598-10606.
11. Maeda J, Ji B, Irie T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci. 2007;27: 10957-10968.
12. 11C]PiB and its multi-modal validation in an APP/ PS1 mouse model of Alzheimer's disease. PLoS ONE. 2012;7:e31310.
13. 11C]PIB uptake in Alzheimer disease. Neurology. 2006;67: 1575-1580.
14. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287-13292.
15. Calhoun ME, Wiederhold KH, Abramowski D, et al. Neuron loss in APP transgenic mice. Nature. 1998;395:755-756.
16. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
17. Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13: 159-170.
18. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotactic Coordinates. 3rd ed. Waltham, Massachusetts: Academic Press, Academic Press; 2008
19. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
20. 18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39: 1784-1795.
21. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA. 2003;100:12462-12467.
22. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006;24:516-524.
23. Lockhart A, Ye L, Judd DB, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem. 2005;280: 7677-7684.
24. Wu C, Bowers MT, Shea JE. On the origin of the stronger binding of PIB over thioflavin T to protofibrils of the Alzheimer amyloid-β peptide: a molecular dynamics study. Biophys J. 2011;100:1316-1324.